Latest Breaking News On - General counsel mike ouimette - Page 2 : comparemela.com

Pliant Therapeutics, Inc (NASDAQ:PLRX) General Counsel Mike Ouimette Sells 5,197 Shares of Stock

Pliant Therapeutics, Inc (NASDAQ:PLRX) General Counsel Mike Ouimette Sells 5,197 Shares of Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Nova scotiaUnited statesMike ouimetteLeerink partnrsRoyal bankBlackrock incSwiss national bankDimensional fund advisorsPliant therapeutics incAcadian asset managementWells fargo companyLord abbettPliant therapeutics company profileNeedham companyPliant therapeuticsGet free report

Pliant Therapeutics (NASDAQ:PLRX) Sets New 12-Month Low at $14 12

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report)’s stock price reached a new 52-week low on Wednesday . The stock traded as low as $14.12 and last traded at $14.15, with a volume of 14016 shares trading hands. The stock had previously closed at $14.78. Analyst Ratings Changes Several equities analysts recently issued reports on […]

Hong kongUnited statesMike ouimetteLeerink partnrsSwiss national bankJpmorgan chase coFirst light asset managementSecurities exchange commissionRoyal bankFernwood investment managementPliant therapeutics incY intercept hong kong ltdNeedham companyPliant therapeuticsGet free reportTherapeutics stock down

Pliant Therapeutics (NASDAQ:PLRX) Rating Reiterated by HC Wainwright

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $50.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 199.22% from the company’s previous close. PLRX has been the […]

United statesMike ouimetteSecurities exchange commissionOsaic holdings incJpmorgan chase coCantor fitzgeraldUs bancorpLife insurance coNeedham companyTower research capitalPliant therapeutics incRoyal bankPliant therapeuticsGet free reportHans hullExchange commission

Pliant Therapeutics (NASDAQ:PLRX) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Free Report) in a report published on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $63.00 target price on the stock. A number of other equities research analysts also recently weighed in on the company. HC Wainwright reiterated a buy rating […]

United statesHong kongEric lefebvreMike ouimetteJpmorgan chase coY intercept hong kong ltdCantor fitzgeraldTekla capital managementNeedham companyCanaccord genuity groupPliant therapeutics company profilePliant therapeutics incFernwood investment managementSecurities exchange commissionPliant therapeuticsFree report

Pliant Therapeutics, Inc (NASDAQ:PLRX) Given Consensus Rating of Buy by Brokerages

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have been assigned an average rating of “Buy” from the eleven brokerages that are presently covering the firm, Marketbeat reports. Eleven analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have issued a report on the […]

United statesMike ouimetteFernwood investment managementVirtu financialPliant therapeutics incTekla capital managementSecurities exchange commissionCantor fitzgeraldRoyal bankCanaccord genuity groupPliant therapeuticsGet free reportGenuity groupTherapeutics trading downHans hullExchange commission